Sinovac obtains third H1N1 vaccine order from Chinese Government

29 October 2009

Your browser does not support inline frames or is currently configured not to display inline frames.
Sinovac Biotech Ltd. (NYSE:SVA), a leading provider of
biopharmaceutical products in China, has received its third purchase
order for its H1N1 vaccine, PANFLU.1, from China's Ministry of Industry
and Information Technology for the national stockpiling plan.

Under this purchase order, Sinovac is required to produce an additional
5.19 million doses of PANFLU.1 (15ug/0.5ml) for the Chinese central
government. Out of today's announced PANFLU.1 order, Sinovac is required
to complete delivery of 2.89 million doses to the appointed provincial
and municipal governments by the end of this year and supply the
remaining 2.3 million doses for the central government stockpiling.

The latest 5.19 million dose purchase order is in addition to an
initial order for 3.3 million doses and second order for 3 million doses
received by Sinovac from the Ministry of Industry and Information
Technology of China on September 4, 2009 and September 30, 2009,
respectively, for a total of 11.49 million doses.

Separately, Sinovac also announced that it competed and successfully
won the bidding process to supply its seasonal flu vaccine, Anflu, to
the Shanghai government. This marks Sinovac's entry into a new public
market for its seasonal flu vaccine. The purchase plan from the Shanghai
government reflects an expansion of government purchase programs for the
seasonal flu vaccine. As part of the beneficial policies for citizens of
Shanghai, certain Shanghai citizens will receive inoculation against
influenza for free or with certain allowances.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented,
"We are very proud to be supplying our H1N1 vaccine to the Chinese
government and are confident that we can complete the national H1N1
vaccine stockpiling task in a timely manner. We continue to work towards
our goal of providing citizens of China with affordable,
international-quality vaccines. The agreement with the Shanghai
Municipal Center for Disease Control and Prevention brings us closer to
our goal as it opened up another important public market in China."